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There is an association between hemodialysis session length
and mortality independent of the effects of session duration
on urea clearance. However, previous studies did not
consider changes in session length over time nor did they
control for the influence of time-dependent confounding.
Using data from a national cohort of 8552 incident patients
on thrice-weekly, in-center hemodialysis, we applied
marginal structural analysis to determine the association
between session length and mortality. Exposure was based
on prescribed session length with the outcome being death
from any cause. On the 31st day after initiating dialysis, the
patients were considered at-risk and remained so until death,
censoring, or completion of 1 year on dialysis. On primary
marginal structural analysis, session lengths o4h were
associated with a 42% increase in mortality. Sensitivity
analyses showed a dose–response relationship between
session duration and mortality, and a consistency of findings
across prespecified subgroups. Our study suggests that
shorter hemodialysis sessions are associated with higher
mortality when marginal structural analysis was used to
adjust for time-dependent confounding. Further studies are
needed to confirm these findings and determine causality.
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Over the past several decades, dialysis dose has been
measured in terms of, and titrated with respect to, urea
kinetics. In 1985, Gotch and Sargent1 introduced the concept
of single pool Kt/V, a measure of dialysis adequacy that
attempts to match the degree of urea clearance to metabolic
needs. In the intervening years, single pool Kt/V, and the
related equilibrated Kt/V (eKt/V), have been largely adopted
as the primary indices of dialysis adequacy.2
Over the past decade, the validity of Kt/V (single pool
and/or equilibrated) as an outcome measure has been
debated. Lowrie et al. have argued that since both greater
urea clearance (K*t) and greater volume of distribution (V)
are each associated with improved survival,3 dividing the two
(that is, placing V in the denominator) is counter-intuitive,
and guiding therapy by the Kt/V metric may therefore lead to
disadvantageously low levels of urea removal in patients with
already poor projected survival on the basis of small body
size.4 In addition, in the present era of high-efficiency
dialyzers (which enable rapid urea removal), the singular
focus on urea kinetics may result in session lengths that are
too short to enable adequate clearance of larger, charged, or
protein-bound molecules, and moderate, well-tolerated rates
of fluid removal for many patients.5,6
Several studies have examined the association between
dialysis session length and mortality independent of (that is,
adjusted for) Kt/V.5,7,8 Although many results lent credence
to an association between shorter session length and mortality,
these studies were beset by methodological shortcomings.
Specifically, all studies considered session length as of a
baseline value, which does not reflect the commonplace
clinical practice of titration in response to clinical and
biochemical circumstances. Moreover, none of the studies
accounted for the potential of time-dependent confounding
of the session length–mortality association. Time-dependent
confounders are variables that are influenced by previous
exposure, that then influence subsequent exposure, and are
also associated with the outcome.9–12 It has been shown that
in the presence of time-dependent confounding, standard
methods of statistical adjustment (as used by the previous
studies cited above) yield biased (that is, inaccurate) estimates
of causal association, even when covariates are time-updated
in the statistical model. Fortunately, novel statistical methods
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have been developed that enable more accurate estimation
of causal associations in the presence of time-dependent
confounding, among them marginal structural analysis.11,12
To determine whether shorter session length is associated with
higher mortality while considering time-dependent confounding,
we undertook a series of marginal structural analyses in which we
examined the associations between session length and mortality,
considering the former as a time-varying exposure. For
comparative purposes, we also present the results of standard
analyses—those in which session length was considered as of
baseline levels, and those in which it was considered as a time-
varying exposure using standard methods of statistical adjust-
ment—to emphasize the potential advantages of marginal
structural analysis as a means of more accurately quantifying
associations when exposures are titrated over time.
RESULTS
The source cohort contained data on 10,044 patients who
initiated incenter maintenance hemodialysis at any Fresenius
Medical Care North America facility between June 2004 and
August 2005. After excluding minors (n¼ 14), patients who
did not survive until the start of at-risk time (dialysis day 31;
n¼ 603) and those with insufficient covariate data for
analysis (n¼ 875), 8552 subjects qualified for inclusion in
the study. The mean age was 62.3±15.4 years, 54.8% were
male and 40.5% were of nonwhite race (Table 1). Excluded
patients were significantly more likely than study participants
to be older, nonwhite, dialyze through a catheter, have lower
blood pressure, serum albumin, and creatinine, be prescribed
shorter session lengths, and less likely to have congestive
heart failure (CHF) (Table 1).
The distribution of baseline session length (that is, the last
observed over dialysis days 0–30) is shown in Figure 1a. Given the
discrete pattern observed, session length was categorized as
shorter (o240min) or longer (X240min) in primary analyses;
secondary analyses considered session length categorized as
p180, 181–239, or X240min and as a continuous variable.
Representative changes in session length during at-risk time are
depicted in Figure 1b. For clarity, the figure shows transitions
occurring between months 0, 3, and 6; analytically, session length
was updated with each new order (time-updated analyses) or at
monthly intervals (marginal structural analyses). Overall, 1698
subjects (19.9%) transitioned at least once between shorter
(o240min) and longer (X240min) session length; 2478
(29.0%) transitioned at least once among p180, 181–239, and
X240min session length strata.
At-risk time began on dialysis day 31 and continued until each
subject died, was censored, or completed 1 year on dialysis (the
last day of complete follow-up). Censoring criteria included
transfer of care (n¼ 851), recovery of kidney function (n¼ 236),
withdrawal from dialysis (n¼ 336), and receipt of a kidney
transplant (n¼ 213). Overall 8552 subjects contributed 78,798
patient-months of at-risk time, during which 1047 died; 5869
subjects remained alive and on dialysis as of the end of study.
Baseline and Time-updated Analyses
In baseline analyses, exposure and covariates were defined as
the last value observed during the baseline exposure period
Table 1 | Baseline description of study participants and excluded patients
Variable Study cohort (n=8552) Excluded (n=1492a) Pb
Age (years) 62.3±15.4 65.0±16.1 o0.001
Male 4686 (54.8%) 815 (54.6%) 40.9
Nonwhite race 3461 (40.5%) 467 (31.3%) o0.001
BMI (kg/m2) 26.3 (22.5–31.2) 26.2 (22.3–31.4) (n=1388) 0.8
Vascular access o0.001
Fistula 2347 (27.4%) 126 (11.4%)
Graft 1031 (12.1%) 64 (5.8%)
Catheter 5174 (61.5%) 915 (82.8%) (n=1105)
CHFc 1642 (19.2%) 234 (15.7%) 0.01
eKt/V 1.35±0.32 1.35±0.35 (n=688) 40.9
Blood pressure (mmHg)
Systolic 147.8±28.2 138.8±30.0 o0.001
Diastolic 76.1±16.9 71.7±17.5 (n=1491) o0.001
Albumin (g/dl) 3.7±0.5 3.4±0.6 (n=1490) o0.001
Creatinine (mg/dl) 7.4±3.1 6.1±3.0 (n=1403) o0.001
Session length (min) 225 (210–240) 210 (210–240) (n=1483) o0.001
Deaths 1047 222
Mortality rate (deaths per 1000 pt-years) 161.7 (152.2–171.8) 509.5 (446.7–581.2) o0.001
Abbreviations: BMI, body mass index; CHF, congestive heart failure; CI, confidence interval; pt-years, patient years.
Continuous data expressed as mean±s.d. or median (inter-quartile range) as appropriate. Categorical data presented as n (%). Mortality rates expressed as point estimate
(95% CI).
aExcept where noted.
bComparing study participants to excluded patients. Continuous variables compared using Student’s t-test or Wilcoxon rank–sum test as appropriate, categorical variables
compared using w2 test, survival data compared using log rank test.
cCHF defined as diagnosis code on Medical Evidence Form 2728 or attributed hospitalization during the baseline period.
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(dialysis days 0–30), and used to predict survival in the
subsequent at-risk period. Over the baseline exposure period,
last observed session length was highly correlated with mean
session length (r¼ 0.94), suggesting that classification of
exposure in terms of the former was reflective of the
cumulative exposure to dialysis during this interval. Shorter
session length (o240min) was observed for 54.7% of subjects.
On unadjusted analysis, shorter session length was
significantly associated with higher mortality: HR (95% CI)
1.24 (1.10–1.41; P¼ 0.001) (Figure 2). On multivariable
adjustment, the association between shorter session length
and mortality was attenuated and no longer statistically
significant: HR (95% CI) 0.89 (0.78–1.02; P¼ 0.09) (Figure 2).
As session length is not static, but rather, typically titrated
in response to clinical circumstances, we fit time-updated
proportional hazards models to estimate the association
between session length and mortality. In these models, we
updated session length with each new order, along with blood
pressure, eKt/V, presence or absence of CHF, serum albumin,
and creatinine (as described in Materials and Methods).
Shorter session length (o240min) was observed in 52.9% of
all patient-time.
On unadjusted analysis, shorter session length was
significantly associated with higher mortality: HR (95% CI)
1.33 (1.18–1.51; Po0.001) (Figure 2). On multivariable
adjustment, the association between shorter session length
and mortality was attenuated and no longer statistically
significant: HR (95% CI) 1.00 (0.87–1.14; P40.9) (Figure 2).
Marginal Structural Analysis
To better account for the influence of time-dependent
confounding on the session length–mortality association,
we applied marginal structural analyses. In these analyses,
session length and time-varying covariates were updated at
each month of study. Overall, shorter session length
(o240min) was observed in 52.4% of all patient-months.
In the unweighted (that is, unadjusted) model, there was a
significant association between shorter session length and
death similar to that seen in the unadjusted time-updated
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Figure 1 |Observed hemodialysis session lengths among study
cohort. (a) Distribution of observed session length at baseline
(n¼ 8552). (b) Representative transitions among strata of session
length at baseline, months 3 and 6. At the start of at-risk time (at-risk
day 0, corresponding to dialysis day 31), 2020 (23.6%) patients
had session length p180min; of these 303 (15.0%), 703 (34.8%),
and 852 (42.2%) had session length of X240, 181–239, and
p180min, respectively, at the start of month 3; the remaining
162 (8.0%) had died or were censored by that time. Interpretation
is analogous for other session-length strata and time intervals.
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Figure 2 |Hazard ratios (95% CIs) for all-cause mortality for
shorter session length (o240min) in baseline, time-updated,
and marginal structural analyses. The referent category is
session length X240min (hazard ratio¼ 1 by definition; not
shown). Gray bars represent unadjusted estimates. White bars
represent estimates adjusted for age, sex, race (white versus
nonwhite), vascular access (fistula, graft, catheter), body mass
index (p20, 20–25, 25–30, and 430 kg/m2), congestive heart
failure, eKt/V (p1.0, 1.0–1.2, 1.2–1.4, 1.4–1.6, 41.6), systolic blood
pressure, serum albumin, and creatinine. CI, confidence interval.
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model: HR (95% CI) 1.38 (1.21–1.57; Po0.001) (Figure 2).
However, unlike with baseline and time-updated models, on
multivariable adjustment (through application of stabilized
weights), the association between shorter session length and
mortality was not attenuated, and remained highly statisti-
cally significant: HR (95% CI) 1.42 (1.24–1.62; Po0.001)
(Figure 2).
To examine the robustness of this finding, we examined
the association between shorter session length and mortality
in prespecified subgroups of study patients using marginal
structural models analogous to those above. In each model,
weights were reestimated in the restricted population using
models otherwise analogous to those from the full popula-
tion. Adjusted estimates of association between shorter
session length and mortality were qualitatively similar in all
12 subgroups, and reached conventional levels of statistical
significance in 10 of 12 (Figure 3).
To assess for a potential dose response, we fit models in
which session length was categorized as p180, 181–239, or
X240min (observed in 12.2, 40.2, and 47.6% of patient-
months, respectively). In both the unadjusted (unweighted)
and multivariable adjusted (weighted) models, incremental
decrements in session length corresponded to incremen-
tally higher risks of mortality; all values were statistically
significant relative to the referent group receiving ses-
sion lengthX240min (Figure 4). In addition, we fit a model
in which session length was considered as a continuous
variable. On marginal structural adjustment, each 15min
decrement in session length was associated with a hazard
ratio (95% CI) for all-cause mortality of 1.12 (1.08–1.16;
Po0.001).
DISCUSSION
In this study, we sought to determine whether hemodialysis
session length was associated with mortality under a thrice-
weekly paradigm. The primary finding was that shorter
session length was associated with higher mortality. Our
findings differed depending on the analytic strategy adopted;
using marginal structural modeling, we were better able to
adjust for time-dependent confounding on the basis of eKt/V
and markers of nutritional (serum albumin and creatinine),
hemodynamic status (blood pressure and CHF), and case-
mix. Findings seemed robust on sensitivity analyses in which
prespecified subgroups of patients were considered.
Numerous observational studies have examined the
relation between hemodialysis session length and mortality,
with conflicting results. In a sample of prevalent hemodialysis
patients from Australia and New Zealand, Marshall et al.8
showed that shorter session length (therein defined as
o3.5 h) was associated with significantly higher mortality
(HR 1.75; 95% CI 1.27–2.40) compared with a referent group
receiving 4–4.4 h treatments. Similarly, in a multinational
sample of prevalent hemodialysis patients from the Dialysis
Outcomes and Practice Patterns Study (DOPPS), Saran et al.5
showed that session lengths o211 and 211–240min were
associated with significantly higher mortality (HR 1.34,
Po0.001 and 1.19, P¼ 0.01, respectively) compared with a
referent group receiving4240-min treatments. In a national
sample of prevalent Fresenius Medical Care patients from
2002, Lowrie et al.7 showed a near linear association between
shorter session length and a greater log-hazard for all-cause
mortality. Conversely, several studies failed to show a session
length and mortality,13,14 however these studies were based
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Figure 3 |Adjusted hazard ratios (95% CIs) for all-cause
mortality for shorter session length (o240min) in
prespecified subgroups. The referent category was session
length X240min. Estimates were adjusted through marginal
structural analysis in an analogous manner to that used in the
primary analysis; stabilized weights were reestimated for each
subgroup. Baseline (B/l) eKt/V and congestive heart failure (CHF)
refer to those values updated through dialysis day 30; baseline
hospitalization refers to any hospitalization occurring between
dialysis days 0–30.
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on data from the late 1980’s and early 1990’s—an era when
shorter treatment times, non-volumetric ultrafiltration and
acetate-based buffers were the norm—and their applicability
to contemporary hemodialysis patients remains uncertain.
Our study differed from previous studies in several
important ways. First, unlike previous studies, which
considered session length at baseline only, our study
examined session length as a time-varying exposure, which
minimizes the potential for exposure misclassification bias
stemming from manipulation of session length, as is
commonplace in clinical practice. Second, our study
considered a cohort of strictly incident hemodialysis patients,
thereby minimizing the potential for survivor bias (that is,
depletion of susceptibles), and informing decisions regarding
session length at a time when dialysis-associated mortality is
highest and consideration of session length most acute. Most
importantly, we used marginal structural analysis to appro-
priately adjust for the influence of time-dependent
confounding. Time-dependent confounders are variables
that (like typical confounders) are associated with future
exposure and outcome, but (unlike typical confounders) are
influenced by previous exposure. It has been proven that in
the presence of time-dependent confounding, conventional
statistical methods yield biased (that is, incorrect) estimates
of causal association.11,12 To understand this, consider the
example of eKt/V. Measured eKt/V in month 2 will influence
session length in month 3, and will also be associated with
future survival. In this sense, eKt/V functions as a typical
confounder, and necessitates statistical adjustment lest
estimates be biased. However eKt/V in month 2 will be
influenced by session length in month 1, and this pathway
(session length-eKt/V-mortality) is one means by which
session length might influence mortality. In this sense, eKt/V
functions as a causal pathway intermediate, and any statistical
adjustment for it will lead to biased (toward the null)
estimates of the session length–mortality association. Con-
ventional statistical methods cannot selectively adjust for the
confounding effects of eKt/V without simultaneously (and
inappropriately) adjusting for its pathway-intermediate
effects, thus ensuring that results will be biased. Though
presented in the context of eKt/V, these considerations are
true for time-dependent confounders in general.
Marginal structural modeling is one statistical technique
capable of adjusting for confounding by time-dependent
confounders without inappropriately adjusting for their
pathway-intermediate effects;11,12 its use in this regard has
become increasingly common in the nephrology litera-
ture.15–18 Under the untestable assumption that all time-
dependent confounders are included and appropriately
specified in the statistical model (an assumption no different
from that implicit in standard multivariable adjustment),
marginal structural models render estimates that approx-
imate randomized controlled trials.11 In these analyses, use of
standard proportional hazards analyses suggested no associa-
tion between shorter session length and mortality, which
likely resulted from the inappropriate ‘adjusting away’ of the
effects of session length on mortality mediated through
improvements in nutritional status, small molecule clearance
and hemodynamics. Conversely, on marginal structural
analysis, it seemed that shorter session length was potently
associated with higher mortality.
Ultimately, the best strategy to eliminate the influence of
time-dependent confounding is through randomization of
subjects to fixed treatment protocols. To date, only two large
randomized trials of the effect of dialysis dose on patient
outcomes have been conducted. The National Cooperative
Dialysis Study randomized patients in a 2 2 factorial design
to high or low blood urea nitrogen levels and shorter or
longer session lengths.19 Findings suggested a near-significant
association between shorter session lengths and increased
morbidity (P¼ 0.056), but no effect on mortality. However,
the National Cooperative Dialysis Study was underpowered
to examine mortality as an endpoint, in part due to early
termination at the time of interim analysis. The Mortality
and Morbidity in Hemodialysis (HEMO) study randomized
subjects to high or standard equilibrated Kt/Vurea (and high
versus low flux dialysis membranes), and found no associa-
tion between either intervention and mortality.20 It is
important to note that subjects in the HEMO study were
not randomized to various levels of session length per se
(rather to levels of Kt/Vurea, which can be manipulated
through multiple means); thus the study does not constitute
a true randomized trial of session length.21 As such,
conclusions with respect to the influence specifically of
session length are subject to some of the same limitations (for
example, bias, confounding) as would accompany an
observational study.
The precise mechanism through which session length
might influence mortality is not clear. It has been shown that
longer session lengths result in improved removal of urea,
creatinine, phosphorous, and beta-2 microglobulin even
when Kt/Vurea is held constant.
6 Therefore, it is possible that
some of the true effects of longer session length stem from
enhanced solute clearance beyond what is reflected by
Kt/Vurea. In addition, longer session length enables ultra-
filtration to proceed at a slower rate, which may improve
blood pressure control and facilitate more consistent
attainment of dry weight.22,23 These effects may, in turn,
attenuate left ventricular hypertrophy, fibrosis, and diastolic
dysfunction, all of which are associated with mortality in
patients on maintenance dialysis.24–27 Some have argued that,
given the inherent inter-relatedness of session length and
Kt/V, that the association between session length and
mortality may stem from inappropriately low Kt/V among
patients receiving shorter session lengths.28 Nonetheless, that
the association between session length and mortality
remained potent and statistically significant among the
subgroup of patients with eKt/V41.2 (Figure 3) is evidence
that session length may influence mortality even when eKt/V
conforms to the current standard of care.2
Several limitations of this study bear mention. Most
notably, our study was designed to measure the association
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between session length and mortality within the context of
conventional thrice-weekly, incenter hemodialysis. Specifi-
cally, we did not include patients receiving short-daily or
extended dialysis (incenter/at home, diurnal/nocturnal), and
therefore, we cannot determine the associations of session
length or changes in session length among patients on more
frequent or more intensive hemodialysis schedules. Although
our findings support the hypothesis that more dialysis might
reduce mortality and/or morbidity, definitive conclusions
must await the results of dedicated clinical trials, such as the
ongoing Frequent Hemodialysis Network trials.29 Studies
such as ours cannot replace clinical trials (which may fall
short in power and generalizability) but can and should
contribute to the evidence based on which clinical decisions
are made in practice.
As with any observational study, our study is subject to the
potential influence of residual confounding. To minimize this
concern, we adjusted estimates for many factors that may
confound the association between session length and
mortality such as demographics, anthropometrics, and
indices of small molecule clearance, hemodynamics and
nutrition. Of note, we lacked data on interdialytic weight
gain, which may influence decisions on session length and
may also be directly related to mortality and morbidity.
However, inasmuch as patients with larger interdialytic
weight gains are more likely to have longer session lengths
and are more likely to die,30–33 any bias would be toward the
null and would not explain our findings. In addition, we
tracked prescribed (not delivered) session length. This
approach, though necessitated by the available data, is
consistent with intention-to-treat principles, and residual
confounding on this basis would be expected to bias
estimates toward the null assuming either that early
termination of dialysis sessions was unrelated to prescribed
duration, or (as might be more likely) that patients
prescribed longer session lengths were more likely to
terminate prematurely. Again, this would not explain the
observed association between shorter session length and
mortality, and may have rendered our findings conservative.
Finally, exclusion of some patients may limit generalizability
of findings to certain patient groups, most notably those who
have extremely limited survival on dialysis. Nonetheless,
given the modest (30 day) survival requirement, and our
large and diverse study population, we believe that our results
do generalize to the vast majority of chronic dialysis patients
for whom consideration of session length is of issue.
In conclusion, when applied to data from this large cohort
of incident hemodialysis patients, marginal structural
analysis suggests that shorter prescribed hemodialysis
session length is potently and independently associated with
higher all-cause mortality at 1 year. Differences in findings
between marginal structural and proportional hazards
analyses may point to the ability of the former to
appropriately adjust for time-dependent confounding.
Further studies are needed to confirm and extend these
findings.
MATERIALS AND METHODS
Study Population
This protocol was deemed exempt by the Partners Health Care
Institutional Review Board. We conducted a nonconcurrent cohort
study of patients in the ArMORR cohort. Details of the source cohort
have been previously published.15,34 Briefly, the Accelerated Mortality on
Renal Replacement (ArMORR) cohort contains data on 10,044 patients
who initiated incenter maintenance hemodialysis at any Fresenius
Medical Care Unit in North America (FMC-NA) between June 2004
and August 2005. Of these, we excluded minors (age o18 years),
patients who did not survive until the start of at-risk time (dialysis day
31), and those with insufficient covariate data for analysis.
Study Data
All study data were collected prospectively. Demographic and
comorbid disease characteristics were recorded as of dialysis
initiation. Time-updated data were available for session length
(updated with each new order), seated pre-dialysis blood pressure
(updated at each treatment), and laboratory data (updated with
each measurement, typically at intervals of 2–4 weeks). All serum
and urine tests were performed in a centralized laboratory (Spectra
Laboratories, Rockleigh, NJ, USA). Equilibrated Kt/V was calculated
by formal urea kinetic modeling. Presence of pre-existing CHF was
assessed at dialysis initiation, and patients’ status were updated
(where necessary) at the time of attributed hospitalization (Inter-
national Classification of Disease-9 codes 276.6, 402.x1, 404.01,
404.11, 404.91, 404.03, 404.13, 404.93, 425.xx, 428.xx); all
hospitalization data were rigorously collected and reconciled by
dialysis unit personnel as previously described.15
Statistical Analysis
All analyses were conducted using STATA 10.0MP (College
Station, TX, USA). Continuous variables were examined
graphically, described in terms of their means and standard
deviations or medians and inter-quartile ranges, and compared
across groups using Student’s t-test or the Wilcoxon rank–sum
test as appropriate. Categorical variables were described by
frequency distribution and compared across groups using
contingency tables and w2 testing.
Unadjusted associations between predictors and outcome were
explored using Kaplan Meier methods, log rank testing, and unadjusted
proportional hazards models. Adjusted associations between predictors
and outcome were estimated by fitting multivariable proportional
hazards models. Covariates were selected on the basis of biological
plausibility and clinical precedent; all were forced into multivariable
models. For continuous covariates the linearity assumption was tested
graphically (by Martingale residuals) and by comparison of model fit
(by Akaike’s Information Criterion) between non-nested models in
which the covariate was specified as a linear and categorical term.
Those variables demonstrating gross violation of the linearity
assumption were entered as categorical terms in the final multivariable
models. The overall covariate vector in the primary analysis consisted
of the following: age, sex, race (white, nonwhite), vascular access
(fistula, graft, catheter), body mass index (p20, 20–25, 25–30,430 kg/
m2), CHF, eKt/V (p1.0, 1.0–1.2, 1.2–1.4, 1.4–1.6,41.6), systolic blood
pressure, serum albumin, and creatinine. Results of all analyses were
nearly identical when body mass index and eKt/V were specified as
linear terms, when diastolic blood pressure was substituted for systolic
(strong colinearity precluded inclusion of both simultaneously;
r¼ 0.72), and when height and weight were substituted for body mass
index (data not shown).
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We estimated the parameters of a marginal structural propor-
tional hazards model using a pooled logistic regression model as
previously described.11,12 In these analyses, each patient’s experience
was decomposed into individual patient-months. For each patient-
month, the probability of survival was estimated as a function
of the patient’s session length measured at month’s start, and the
month of dialysis (to allow for differential baseline probability of
survival according to time on dialysis); robust variance estimates
were used to account for nonindependence of observations within
patient.
Marginal structural models were adjusted by application of
stabilized weights based on the probability that a patient had his/her
observed session length and on the probability of censoring.11,12
Stabilized probability of exposure weights were defined as the ratio
of two terms: the numerator the probability that each subject had
his/her observed session length based on previous session length and
baseline covariates; the denominator the probability that each
subject has his/her observed session length based on previous session
length, and covariates considered both at baseline and as of the
previous month. In the primary marginal structural analyses, each
was estimated using a separate pooled logistic regression model in
which session length was categorized as o240 or X240min.
Secondary analyses considered session length as p180, 181–239 or
X240min; multinomial logistic regression models were used to
estimate the probability of exposure. Stabilized probability of
censoring weights was estimated in a completely analogous manner
except that no term was included for the previous month’s session
length. Fuller detail regarding specification of marginal structural
models is given in online supplemental materials.
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